Altus Pharmaceuticals Inc. (Nasdaq: ALTU) reported disappointing preliminary results from a late stage clinical trial of its treatment for cystic fibrosis patients with pancreatic insufficiency, Trizytek. An analyst downgraded the biopharmaceutical sending the stock price skidding $2.39 to $2.55.
Disappointing Test Results For Altus Pharmaceuticals
August 12, 2008 at 14:29 PM EDT
